In silico studies of medicinal compounds against hepatitis C capsid protein from north India

Shilu Mathew1, Muhammad Faheem2, Govindaraju Archunan3

  • 1Post Graduate Department of Biotechnology, Jamal Mohamed College, Tiruchirappalli, India. ; Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia. ; Department of Animal Science, Bharathidasan University, Tiruchirappalli, India.

Insights

Hepatitis C virus (HCV) capsid core protein is a key target for new antiviral drugs. Four plant-derived compounds, particularly EGCG, show promise in inhibiting HCV by interacting with the core protein, suggesting a new class of antiviral agents.

Area of Science:

  • Virology
  • Drug Discovery
  • Structural Biology

Background:

  • Hepatitis C virus (HCV) infection affects over a million people globally, leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC).
  • Current treatments for HCV have limitations and side effects, necessitating the development of novel antiviral compounds.
  • The HCV capsid core protein is crucial for viral assembly and RNA packaging, making it a prime target for drug development.

Purpose of the Study:

  • To predict the 3D structure of the HCV capsid core protein from Northern India.
  • To screen phytochemical inhibitors for their potential to disrupt HCV core protein interactions.
  • To evaluate the inhibitory activity of selected flavonoids against HCV genotypes prevalent in North India.

Main Methods:

  • 3D structure prediction of HCV capsid core protein.
  • Screening of four phytochemical inhibitors: epigallocatechin gallate (EGCG), ladanein, naringenin, and silybin.
  • Quantitative structure-activity relationship (QSAR) analysis and molecular docking simulations.

Main Results:

  • Molecular docking revealed that EGCG exhibited the highest number of hydrogen bond interactions with the modeled capsid proteins, followed by naringenin and silybin.
  • QSAR analysis supported the correlation between the inhibitory activity and the selected bioflavonoids.
  • The study identified potential structure-based antiviral compounds targeting the HCV virion capsid.

Conclusions:

  • The screened bioflavonoids, particularly EGCG, demonstrate significant potential as inhibitors of the HCV capsid core protein.
  • These findings suggest a new class of potent antiviral agents for HCV infection.
  • Further in vitro and in vivo studies are required to validate the efficacy of these compounds.